Information Provided By:
Fly News Breaks for January 28, 2020
INCY
Jan 28, 2020 | 10:38 EDT
Piper Sandler analyst Tyler Van Buren says that TRuE-AD2 - the first of Incyte's two pivotal topical rux studies in atopic derm - hitting its primary endpoint "is of course positive news," but it is impossible to know how positive the outcome is until he sees the data presentation at an upcoming medical meeting. While the details are "incredibly limited," the analyst maintains his positive stance on topical rux as he awaits the upcoming data presentation. Van Buren has an Overweight rating and a $95 price target on the shares.
News For INCY From the Last 2 Days
INCY
INCY
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.